Foghorn Therapeutics Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Foghorn Therapeutics Inc. (FHTX) on April 25, 2025, with the earliest event reported on that date. The filing addresses corporate governance changes, specifically the appointment of two new independent directors to the Board of Directors, effective May 1, 2025.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on director appointments and associated compensation arrangements.
Material Changes
The primary material change is the expansion of the Board of Directors with two new members:
- Stuart Duty: Appointed as a Class II independent director and member of the Audit Committee.
- Neil J. Gallagher, M.D., Ph.D.: Appointed as a Class II independent director and member of the Science Committee.
Both appointments were made to ensure compliance with Nasdaq listing standards regarding independent audit committee membership.
Compensation and Governance Details
Both new directors received identical initial equity grants and similar cash retainers under the Company's Non-Employee Director Compensation Policy:
- Equity Grant: Each received an option to purchase 50,000 shares of common stock, vesting in three equal tranches over three years.
- Stuart Duty Cash Retainer: $40,000 annual base plus $7,500 for Audit Committee service (pro-rated for 2025).
- Neil J. Gallagher Cash Retainer: $40,000 annual base plus $5,000 for Science Committee service (pro-rated for 2025).
As of May 1, 2025, the Audit Committee will consist of three independent members, satisfying Nasdaq Listing Rule 5605(c)(2)(A).
Investor Verification Checklist
- Verify the effective date of the new directors' terms (May 1, 2025) and their expiration at the 2025 Annual Meeting.
- Confirm the pro-rated cash compensation amounts for the partial year of 2025.
- Review the attached press release (Exhibit 99.1) for additional biographical details on the new directors.
- Note that this filing contains no financial results; refer to the most recent 10-Q or 10-K for financial metrics.